The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Aims: Albuminuria reduction is essential for renal and cardiovascular protection. We characterized the efficacy of dapagliflozin, a sodium‐glucose co‐transporter 2 inhibitor, on albuminuria. Secondly, we assessed whether the albuminuria‐lowering effect varies among patients, and whether this variability in response is reproducible. Material and methods: A double‐blind, randomized, placebo controlled crossover trial was conducted. Patients with type 2 diabetes and albumin:creatinine ratio > 100 mg/g on a stable dose of an angiotensin‐converting enzyme inhibitor ( ACEi ) or angiotensin receptor blocker ( ARB ) were enrolled. Patients were assigned to 6‐week treatment periods with dapagliflozin 10 mg/d or placebo in random order, separated by 6‐weeks wash‐out periods. After the 2 treatment periods, half of the patients were re‐exposed for 6 weeks to dapagliflozin 10 mg/d. Primary outcome was change in 24‐hour urinary albumin excretion rate (24 h UAE ). To assess reproducibility in individual albuminuria response, responses from the first and second exposure to dapagliflozin were correlated. Results: A total of 33 patients (age, 61 years; female gender, 24.2%; median 24 h UAE , 470 mg/24 h) completed the study. Dapagliflozin, as compared to placebo, reduced 24 h UAE by 36.2% (95% CI , 22.9‐47.2; P < .001). Systolic blood pressure fell by 5.2 mm Hg (95% CI , 0.5‐10.0) and eGFR by 5.3 (95% CI , 2.7‐8.0). All effects were reversible directly after treatment discontinuation. In a subgroup of 15 patients who were exposed twice to dapagliflozin, 24 h UAE responses showed a large variation among individuals: first exposure (range, −76% to +52%) and second exposure (−90% to +95%) and first and second individual response were significantly correlated (r = 0.69 [95% CI , 0.27‐0.89]; P < .004). Conclusion: Dapagliflozin significantly reduces albuminuria when given as adjunct to ACEi or ARB . The albuminuria response to dapagliflozin markedly varies among patients. This variation is not a random phenomenon, but is reproducible upon re‐exposure. These data support personalized therapy approaches to optimize diabetic kidney disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 4×
“Long-term renoprotective effects have also been suggested, based on secondary outcomes from large clinical trials.(8) Potential renoprotective effects are thought to Received: 5 February 2017 Revised: 1 March 2017 Accepted: 8 March 2017”
BackgroundResultInfluentialHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationCherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes
Lambers Heerspink, H. J., de Zeeuw, D., Wie, L., Leslie, B., & List, J. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12127 · Cited by 837 · cited 1×
“Dapagliflozin has been shown to decrease plasma volume and to increase hematocrit to an extent similar to that of hydrochlorothiazide.(3) Previous studies have shown that optimizing extracellular volume through dietary sodium restriction or diuretic use decreases albuminuria, allegedly through potentiating the effects…”
BackgroundHoltkamp, F. A., de Zeeuw, D., Thomas, M. C., Cooper, M. E., de Graeff, P. A., Hillege, H. J. L., Parving, H.-H., Brenner, B. M., Shahinfar, S., & Lambers Heerspink, H. J. (2011) · Kidney International · doi:10.1038/ki.2011.79 · Cited by 364
Canagliflozin slows progression of renal function decline independently of glycemic effects
Heerspink, H. J. L., Desai, M., Jardine, M., Balis, D., Meininger, G., & Perkovic, V. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2016030278 · Cited by 361 · cited 2×
“This finding is in accordance with a previous post-hoc analysis from a large randomized controlled trial demonstrating that long-term effects of the SGLT2 inhibitor canagliflozin on renal function are independent of its glycaemic effects.(14) What could be the mechanism of the albuminuria-lowering effect? As observed…”
ResultSelf-citationDeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293 · cited 1×
“This leads to enhanced glucose and sodium excretion and reductions in HbA1c, plasma volume, body weight and blood pressure.[1-3] Post-hoc analyses from various clinical trials have suggested that SGLT2-inhibitors decrease albuminuria.”
Background
Cited by
Renoprotective effects of sodium-glucose cotransporter-2 inhibitors
Heerspink, H. J. L., Kosiborod, M., Inzucchi, S. E., & Cherney, D. Z. I. (2018) · Kidney International · doi:10.1016/j.kint.2017.12.027 · Cited by 393
Self-citationCherney, D. Z. I., Zinman, B., Inzucchi, S. E., Koitka-Weber, A., Mattheus, M., von Eynatten, M., & Wanner, C. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30182-1 · Cited by 383
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
Self-citationCherney, D. Z. I., Dekkers, C. C. J., Barbour, S. J., Cattran, D., Abdul Gafor, A. H., Greasley, P. J., Laverman, G. D., Lim, S. K., Di Tanna, G. L., Reich, H. N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30162-5 · Cited by 283
Self-citationEffects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers
Dekkers, C. C. J., Petrykiv, S., Laverman, G. D., Cherney, D. Z., Gansevoort, R. T., & Heerspink, H. J. L. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13301 · Cited by 263
Self-citation
Metadata
- Authors
- Petrykiv, S. I., Laverman, G. D., de Zeeuw, D., & Heerspink, H. J. L.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2017-06-08
- Volume
- 19
- Issue
- 10
- Pages
- 1363-1370
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2600135630
- Cited by
- 105
- References
- 7
- FWCI
- 9.70
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients. https://app.cochat.ai/papers/10.1111/dom.12936
- The paper
- Petrykiv, S. I., Laverman, G. D., de Zeeuw, D., & Heerspink, H. J. L. (2017). The albuminuria‐lowering response to dapagliflozin is variable and reproducible among individual patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12936
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.